Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

ClinicalTrials.gov ID: NCT01964989

Public ClinicalTrials.gov record NCT01964989. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to \<72 Months of Age. The study was conducted during the 2013/2014 and 2014/2015 northern hemisphere influenza season.

Study identification

NCT ID
NCT01964989
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Seqirus
Industry
Enrollment
10,644 participants

Conditions and interventions

Eligibility (public fields only)

Age range
6 Months to 71 Months
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2013 (Type not available)
Primary completion
Oct 2015 (Actual)
Completion
Aug 2016 (Actual)
Last update posted
Mar 27, 2023

2013 – 2016

United States locations

U.S. sites
91
U.S. states
24
U.S. cities
73
Facility City State ZIP Site status
222, Novartis Investigational Site Chandler Arizona 85224 —
267, Novartis Investigational Site Harrisburg Arkansas 72432 —
259, Novartis Investigational Site Anaheim California 92801 —
280, Novartis Investigational Site Anaheim California 92804 —
213, Novartis Investigational Site Baldwin Park California 91706 —
407, Novartis Investigational Site Downey California 90241 —
238, Novartis Investigational Site La Puente California 91774 —
411, Novartis Investigational Site Ontario California 91762 —
202, Novartis Investigational Site Paramount California 90723 —
250, Novartis Investigational Site San Diego California 92103 —
293, Novartis Investigational Site San Francisco California 94102 —
243, Novartis Investigational Site Colorado Springs Colorado 80902 —
249, Novartis Investigational Site Denver Colorado 80902 —
229, Novartis Investigational Site Boca Raton Florida 33432 —
416, Novartis Investigational Site Hialeah Florida 33013 —
287, Novartis Investigational Site Hialeah Florida 33106 —
412, Novartis Investigational Site Homestead Florida 34239 —
224, Novartis Investigational Site Melbourne Florida 32935 —
417, Novartis Investigational Site Miami Florida 33015 —
404, Novartis Investigational Site Miami Florida 33144 —
285, Novartis Investigational Site Miami Florida 33172 —
277,Novartis Investigational Site Miami Florida 33412 —
234, Novartis Investigational Site Opa-locka Florida 33054 —
297, Novartis Investigational Site Orlando Florida 32801 —
297, Novartis Investigational vaccine Orlando Florida 32806 —
410, Novartis Investigational Site Sarasota Florida 34239 —
401, Novartis iNvestiagtional Site Atlanta Georgia 30322 —
299, Novartis Investigational Site DeKalb Illinois 60115 —
268, Novartis Investigational Site Peoria Illinois 61602 —
209, Novartis Investigational Site Augusta Kansas 67010 —
210, Novartis Investigational Site Newton Kansas 67114 —
274 Novartis Investigational Site Park City Kansas 67219 —
211, Novartis Investigational Site Wichita Kansas 67205 —
269, Novartis Investigational Site Bardstown Kentucky 40004 —
226, Novartis Investigational Site Louisville Kentucky 40202 —
248, Novartis Investigational Site Louisville Kentucky 40217 —
207, Novartis Investigational Site Louisville Kentucky 40291 —
290, Novartis Investigational Site Louisville Kentucky 40291 —
265, Novartis Investigational Site Haughton Louisiana 71037 —
408, Novartis Investigational Site Mangham Louisiana 71259 —
225, Novartis Investigational Site Metairie Louisiana 70006 —
233, Novartis Investigational Site Metairie Louisiana 70006 —
418, Novartis Investigational SIte Monroe Louisiana 71201 —
262, Novartis Investigational site Annapolis Maryland 21401 —
263, Novartis Investigational Site Frederick Maryland 21702 —
405, Novartis Investigational Site Silver Spring Maryland 20910 —
278, Novartis Investigational Site Saint Paul Minnesota 55108 —
221, Novartis Investigational Site Bellevue Nebraska 68005 —
219, Novartis Investigational Site Fremont Nebraska 68025 —
402, Novartis Investigational Site Omaha Nebraska 68114 —
288, Novartis Investigational Site Omaha Nebraska 68131 —
228, Novartis Investigational Site Omaha Nebraska 68134 —
244, Novartis Investigational Site Henderson Nevada 89014 —
286, Novartis Investigational site Las Vegas Nevada 89106 —
255, Novartis Investigational Site Binghamton New York 13901 —
414, Novartis Investigational Site Brooklyn New York 11201 —
264, Novartis Investigational Site Syracuse New York 13057 —
409, Novartis Investigational Site Boone North Carolina 28607 —
266, Novartis Investigational Site Cary North Carolina 27518 —
403, Novartis Investigational Site Clyde North Carolina 28721 —
240, Novartis Investigational Site Akron Ohio 44311 —
254, Novartis Investigational Site Cleveland Ohio 44122 —
245, Novartis Investigational Site Dayton Ohio 45406 —
281, Novartis Investigational Site Dayton Ohio 45409 —
281, Novartis Investigational vaccines Dayton Ohio 45409 —
256, Novartis Investigational Site Tulsa Oklahoma 74127 —
292, Novartis Investigational Site Erie Pennsylvania 16505 —
270, Novartis Investigational Site Scottdale Pennsylvania 15683 —
220, Novartis Investigational Site Anderson South Carolina 29621 —
406, novartis Investigational Site Barnwell South Carolina 29812 —
272, Novartis Investigational Site Charleston South Carolina 29407 —
232, Novartis Investigational Site Moncks Corner South Carolina 29461 —
291, Novartis Investigational vaccine Spartanburg South Carolina 27262 —
283, Novartis Investigational Site Nashville Tennessee 37203 —
208, Novartis Investigational Site Austin Texas 78705 —
247, Novartis Investigational Site Fort Worth Texas 76107 —
217, Novartis Investigational Site Fort Worth Texas 76135 —
214, Novartis Investigational Site San Angelo Texas 76904 —
400, Novartis investigational Site San Antonio Texas 78229 —
260, Novartis Investigational Site Tomball Texas 77375 —
295, Novartis Investigational Site Layton Utah 84041 —
236, Novartis Investigational Site Salt Lake City Utah 84109 —
212, Novartis Investigational Site Salt Lake City Utah 84121 —
246, Novartis Investigational Site Salt Lake City Utah 84124 —
279, Novartis Investigational Site Spanish Fork Utah 84660 —
282, Novartis Investigational Site Syracuse Utah 84075 —
294, Novartis Investigational Site West Haven Utah 84401 —
201, Novartis Investigational Site West Jordan Utah 84088 —
271, Novartis Investigational Site West Jordan Utah 84088 —
251, Novartis Investigational Site Burke Virginia 22015 —
296, Novartis Investigational Site Vienna Virginia 22180 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01964989, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 27, 2023 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01964989 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →